Ultragenyx Pharmaceutical Inc. - stock earnings
RARE Upcoming estimated earnings
| Date | Actual / Estimated EPS | Low Revenue | Actual / Estimated Revenue | High Revenue |
|---|---|---|---|---|
| May 2, 2024 AfterMarket | -2.03 / -1.79 | - | 108.8 million / 118.5 million | - |
| Aug. 1, 2024 BeforeMarket | - / - | 120.0 million | - / 124.9 million | 130.1 million |
RARE Quarterly earnings
| Date | Earnings | Revenue |
|---|---|---|
| 2024Q1 | -170.7 million USD | 108.8 million USD |
| 2023Q4 | -123.2 million USD | 127.4 million USD |
| 2023Q3 | -159.6 million USD | 98.1 million USD |
| 2023Q2 | -159.8 million USD | 108.3 million USD |
| 2023Q1 | -164.0 million USD | 100.5 million USD |
| 2022Q4 | -151.8 million USD | 103.3 million USD |
| 2022Q3 | -245.1 million USD | 90.7 million USD |
| 2022Q2 | -158.2 million USD | 89.3 million USD |
| 2022Q1 | -152.3 million USD | 79.9 million USD |
| 2021Q4 | -122.5 million USD | 83.4 million USD |
| 2021Q3 | -73.0 million USD | 81.6 million USD |
| 2021Q2 | -122.4 million USD | 87.0 million USD |
| 2021Q1 | -136.1 million USD | 99.4 million USD |
| 2020Q4 | -24.0 million USD | 91.5 million USD |
| 2020Q3 | -68.8 million USD | 81.5 million USD |
| 2020Q2 | 25.3 million USD | 61.7 million USD |
| 2020Q1 | -119.0 million USD | 36.3 million USD |
| 2019Q4 | -93.8 million USD | 35.6 million USD |
| 2019Q3 | -113.0 million USD | 25.8 million USD |
| 2019Q2 | -99.2 million USD | 24.1 million USD |
| 2019Q1 | -96.8 million USD | 18.2 million USD |
| 2018Q4 | -87.8 million USD | 16.3 million USD |
| 2018Q3 | -87.3 million USD | 11.8 million USD |
| 2018Q2 | -52.7 million USD | 12.8 million USD |
| 2018Q1 | 30.3 million USD | 10.7 million USD |
| 2017Q4 | -81.7 million USD | 2.4 million USD |
| 2017Q3 | -79.2 million USD | 198000 USD |
| 2017Q2 | -72.9 million USD | ? USD |
| 2017Q1 | -68.3 million USD | ? USD |
| 2016Q4 | -71.3 million USD | 5000 USD |
| 2016Q3 | -64.9 million USD | 111000 USD |
| 2016Q2 | -56.9 million USD | 17000 USD |
| 2016Q1 | -52.8 million USD | ? USD |
| 2015Q4 | -55.2 million USD | ? USD |
| 2015Q3 | -39.2 million USD | ? USD |
| 2015Q2 | -29.8 million USD | ? USD |
| 2015Q1 | -21.4 million USD | ? USD |
| 2014Q4 | -16.7 million USD | ? USD |
| 2014Q3 | -15.8 million USD | ? USD |
| 2014Q2 | -13.6 million USD | ? USD |
| 2014Q1 | -13.6 million USD | ? USD |
| 2013Q4 | -11.3 million USD | ? USD |
| 2013Q3 | -8.4 million USD | ? USD |
| 2013Q2 | -8.6 million USD | ? USD |
| 2013Q1 | -6.7 million USD | ? USD |
| 2012Q4 | -4.9 million USD | ? USD |
| 2011Q4 | ? USD | ? USD |
RARE Yearly earnings
| Date | Earnings | Revenue |
|---|---|---|
| 2023 | -606.6 million USD | 434.2 million USD |
| 2022 | -707.4 million USD | 363.3 million USD |
| 2021 | -454.0 million USD | 351.4 million USD |
| 2020 | -186.6 million USD | 271.0 million USD |
| 2019 | -402.7 million USD | 103.7 million USD |
| 2018 | -197.6 million USD | 51.5 million USD |
| 2017 | -302.1 million USD | 2.6 million USD |
| 2016 | -245.9 million USD | 133000 USD |
| 2015 | -145.6 million USD | ? USD |
| 2014 | -59.8 million USD | ? USD |
| 2013 | -35.1 million USD | ? USD |
| 2012 | -16.3 million USD | ? USD |
| 2011 | -6.8 million USD | ? USD |
RARE
Price: $42.94
52 week price:
Earnings Per Share: -8.25 USD
P/E Ratio: -5.24
Exchange: NMS
Sector: Healthcare
Industry: Biotechnology
Volume: 449700
Ebitda: -96.8 millionMarket Capitalization: 3.6 billion